Atossa Therapeutics Highlights (Z)-Endoxifen Potential in Duchenne Muscular Dystrophy Research
SEATTLE, May 20, 2026 Atossa Therapeutics announced that a new scientific manuscript exploring the utrophin-modulation potential of (Z)-endoxifen in...
Atossa Therapeutics
Advertisement
Atossa Gains FDA RPD Status for Z-Endoxifen in MAS
SEATTLE, WASHINGTON, May 04, 2026 Atossa Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted...
Atossa Pursues FDA Path for Low-Dose (Z)-Endoxifen in Breast Cancer Prevention
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, announced it has filed a request for a Type C...
Advertisement
